

CLARA claims Medicare Set-Aside

Medicare Set-Aside Allocations (MSAs) provide an estimate of future medical treatment costs for injured claimants to protect Medicare's interests at claim settlement. Currently, obtaining an MSA can take weeks, and numerous back and forth emails with the vendor, not to mention the hefty fees involved. Payers are spending hundreds of millions annually on MSAs, as well as the adjusters' time involved in this process.

CLARA analytics is set to revolutionize this practice by providing MSA services faster, and at vastly reduced costs, including unlimited updates and CMS submission. Our MSA solution alleviates the hassle, enabling adjusters to generate MSAs at any time via our online solution. In addition, CLARA's MSA solution is offered as an integrated feature of CLARA claims, meaning payers will be able to access all claim recommendation features within CLARA claims, as well.

Features

- Automated identification of claims likely to need an MSA based on claim attributes
- Automated MSA report generation at the push of a button
- Ability to combine multiple claims in one MSA to assess cost differences
- MSA updates as often as needed, based on changing treatment under the claim
- Ability to include/ exclude identified co-morbid conditions at time of MSA generation
- MSA reports available in a traditional CMS and EBM-based formats
- CMS submission of final MSA, with amended reviews where indicated

Traditional Solutions

- Speed can take weeks to obtain initial MSA report
- Cost \$2,500+ per report, plus additional costs for CMS submission fees and updates
- Flexibility limited options to customize MSAs
- Consistency MSA development dependent on creator's background and expertise

CLARA analytics MSA Solution

- Speed MSAs generated automatically at the push of a button
- Cost included in CLARA claims including unlimited updates and CMS submission at no additional cost
- ► Flexibility ability to generate MSAs with various options (E.g. easy inclusion of multiple claims under one MSA, inclusion/exclusion of co-morbid conditions, and traditional or EBM-based forecasting)
- Consistency extensive industry expertise with machine learning techniques eliminate human biases in the forecasting of future treatment for the MSA

